Pagoclone going the Zoloft way?
Pfizer nearly rejected Zoloft clinical development twice before going on to market the drug, Indevus tells conference call on Pfizer's termination of pagoclone contract. "Twice in the history of Zoloft, in the early days at Pfizer, the compound was facing cancellation over dose and efficacy issues and obviously Zoloft came through to be one of the most successful antidepressants today," the company said...
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.